CD274 and non-small cell lung carcinoma: Adjuvant pembrolizumab gained FDA approval, irrespective of PD-L1 score, in stage IB (≥ 4 cm), II and IIIA NSCLC, although NCCN guidelines recommended this approach be offered in stage IIB–IIIA, stage IIIB (T3, N2), or high-risk stage IIA (AJCC 8th edition) NSCLC [6].